Takeda Builds on 30-Year Partnership with the World Federation of Hemophilia with a Five-Year Product Donation to the Humanitarian Aid Program

Takeda Builds on 30-Year Partnership with the World Federation of Hemophilia with a Five-Year Product Donation to the Humanitarian Aid Program

−      Program Aims to Help Advance the Standard of Care for People with Inherited Bleeding Disorders in Developing Countries

Osaka, Japan, March 29, 2021 – Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced it has joined the World Federation of Hemophilia’s (WFH) Humanitarian Aid Program with a five-year product donation of coagulation factor and bypassing agents. The WFH’s Humanitarian Aid Program seeks to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries.[1] This donation builds on a 30-year partnership with the WFH, driven by Takeda’s belief that every bleed matters and that all men and women with a rare bleeding disorder, wherever they live, should have access to comprehensive, personalized care.

“At Takeda we recognize the need to advance the standard of care for those living with a rare bleeding disorder, as well as the importance of tackling disparities in access to treatment worldwide. To achieve these ambitions, we have to work together as a community and focus on evidence-based advocacy,” said Julie Kim, president of the Plasma-Derived Therapies Business Unit of Takeda. “This five-year product donation aims to help the WFH in improving access to treatment, including prophylaxis to protect joint health. We are pleased to be able to continue collaborating with the WFH on their flagship advocacy and data collection programs, supporting our ambition to achieve a world without bleeds.”

The WFH and its national member organizations have made significant progress in improving diagnosis and access to care through programs such as the World Bleeding Disorder Registry (WBDR) and the Global Alliance for Progress (GAP) program, both of which are supported by Takeda. The WBDR provides a platform for hemophilia treatment centers around the world to collect standardized patient data to help guide clinical practice. It began in 2018 and has a five-year goal of enrolling 10,000 people with hemophilia across 50 countries.[2] The GAP program aims to close the gap between developed and developing countries in the diagnosis and treatment of people with hemophilia and other bleeding disorders by working with local systems and infrastructures to maximize existing resources and achieve long-term sustainable development.[3] Takeda has been a visionary partner and strong supporter of the GAP program since it was launched in 2003. These programs along with the Humanitarian Aid Program strive to advance the standard of care for patients with hemophilia and other bleeding disorders through evidence-based advocacy.

“Takeda has collaborated with the WFH for over 30 years, playing an important role in several of our programs, including the GAP Program and the WBDR,” said Alain Baumann, CEO of the WFH. “We are thankful that Takeda has now extended their support to the WFH Humanitarian Aid Program. This will allow the WFH to do even more to support bleeding disorders communities in need around the world.”